Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
Answer first: stop waiting on the payer grid, build the case yourself
SUD operators will not get paid for longer, more complex synthetic-drug detox by waiting for Optum, Carelon, or a state MCO to update its authorization grid. Operators have to push the case the other direction: document medical necessity beyond the ASAM Criteria 4th Edition defaults, request single-case agreements (SCAs) with enhanced per diems for xylazine, nitazene, tianeptine, and synthetic-benzodiazepine admissions, and pre-build utilization review (UR) appeal packages that translate atypical clinical courses into language a payer’s UR nurse can actually approve.
The drug supply has changed faster than any payer policy committee. The DEA’s May 2026 Public Safety Advisory warns that fentanyl is now routinely combined with xylazine, nitazenes, cychlorphine, and medetomidine, and notes that new nitazenes tend to be introduced when regulatory actions, enforcement, and drug scheduling put pressure on existing analogues, and DEA has reported 22 unique nitazenes compounds since 2020, 21 of which are listed as Schedule I controlled substances. Meanwhile the payer-side authorization criteria still read like 2018 fentanyl. That gap is where operators are losing money on every admission they should be winning.
What the data actually says (and what payers are still missing)
CDC’s January 2026 NCHS Data Brief No. 549 reports that in 2024, 79,384 drug overdose deaths occurred, resulting in an age-adjusted rate of 23.1 deaths per 100,000 standard population, and that between 2023 and 2024, the drug overdose death rate involving synthetic opioids other than methadone decreased by 35.6% (from 22.2 to 14.3). Good news at the surface. Underneath it, the clinical picture in the bed is harder, not easier.
Polysubstance is now the norm. CDC reports that among 37 states and DC, 47% of drug overdose deaths in 2023 involved both opioids and stimulants. Add the adulterants: laboratory analysis showed that between 2023 and 2024, laboratory data showed a 17 percent rise in nitazene detections among fentanyl-positive drug samples, and in nearly all cases the substances were found together. And tianeptine, the so-called gas-station heroin, is no longer a curiosity: a 2024 study in the Journal of Medical Toxicology found that there were 892 single-substance tianeptine exposures reported to US poison centers from 2015 to 2023, and the rate of exposures increased 1,400% from 2015 to 2023, including a 525% increase from 2018 to 2023, with most exposures associated with moderate (51.5%) or major (12.0%) effects, and 40.1% required medical admission, including 22.9% to a critical care unit.
Xylazine throws the standard COWS-driven authorization model into the ditch. The Penn CAMP best-practices document notes that xylazine withdrawal may conflate the use of COWS scoring to determine buprenorphine readiness, and the time course for opioid withdrawal onset has been skewed from historical descriptions of heroin withdrawal occurring within 6-12 hours of last use to onset of fentanyl withdrawal which may be delayed to 12-24 hours prior to a measurable COWS score greater than 8 or 12. Translation for the contracting team: the UR nurse looking at a payer grid that pays a 3-to-5 day opioid detox is going to deny day 6, 7, and 8, even when the patient is still actively withdrawing from xylazine and a nitazene cocktail.
The operator-side playbook: SCAs, carve-outs, and parity arguments
At a 64-bed residential and withdrawal-management facility in Florida that AHS supports on payer strategy, we rebuilt the admission packet last quarter specifically for synthetic-drug cases. The team stopped sending payers a generic ASAM 4th Edition dimensional summary and started sending a structured medical-necessity narrative: confirmed adulterant exposure on toxicology, COWS plus an alpha-2 withdrawal assessment, autonomic instability data points, and a stated expected length of stay tied to the specific clinical course. Authorization approvals on extended stays jumped, and the days in AR on those cases dropped by roughly 11 days.
Four moves operators should make now:
- Request a single-case agreement before admission, not after the denial. Lead with toxicology (xylazine, nitazene, tianeptine, bromazolam, or other designer benzo), expected length of stay, and a proposed per diem 15 to 35 percent above the standard residential or 3.7 residential withdrawal management rate. Reference the SAMHSA TIP 63 framework and the ASAM Criteria 4th Edition dimensional assessment in the body of the request.
- Pursue rate carve-outs in your next contract cycle. Florida AHCA-contracted MCOs, New Jersey DMAHS plans, and MassHealth ACOs have all entertained acuity-adjusted per diems under their 1115 SUD demonstrations when the operator brings clean outcomes data. A flat per diem set in 2021 does not cover a 2026 xylazine admission.
- Cite MHPAEA directly in commercial denials. The 2024 MHPAEA Report to Congress states that EBSA has requested and reviewed comparative analyses for hundreds of NQTLs, obtained corrections that removed impermissible MH/SUD treatment barriers for more than 7.6 million participants in over 72,000 plans, and ensured payment of wrongfully denied MH/SUD claims. When a commercial payer applies a tighter concurrent review standard to a polysubstance synthetic-drug detox than it would to a comparable medical/surgical admission, that is an NQTL parity argument, and it belongs in your appeal letter, not in a footnote.
- Build the UR appeal scaffold once, use it every time. Pre-write the parity citation, the ASAM dimensional logic, the toxicology attachment, and the physician peer-to-peer talking points. Train the UR coordinator to file within 24 hours of an adverse determination.
The 2024 Report to Congress put it plainly: outcomes data is, and will continue to be, a key indicator of MHPAEA compliance. Operators who can produce that outcomes data on the synthetic-drug cohort have the strongest possible footing in any contract negotiation or appeal.
Compliance side: the documentation has to defend the clinical reality
Higher-acuity admissions invite audit risk if the chart does not match the level of care. At a residential SUD program in Kentucky we worked with from acquisition through licensure, the clinical leadership rewrote admission criteria and physician progress notes specifically to capture xylazine and nitazene exposure, autonomic instability, wound-care needs, and co-occurring sedative-hypnotic withdrawal. That documentation now does double duty: it defends medical necessity to the payer and it satisfies state licensing surveyors looking at whether the residential level of care is appropriate for the acuity in the building.
Three compliance-side guardrails for operators stepping into synthetic-drug acuity:
- Confirm your residential or withdrawal-management licensure covers the acuity you are admitting. Under the ASAM Criteria 4th Edition, residential withdrawal management is the appropriate residential detox setting; if a patient genuinely needs medically managed inpatient care, a free-standing residential license does not stretch that far. State DOH and DCF surveyors will ask.
- Make sure your medical director’s standing orders and protocols are current for alpha-2 agonist withdrawal, nitazene reversal considerations, and synthetic-benzodiazepine taper. A peer-reviewed systematic review in PMC concluded that for xylazine there is no antidote or evidence-based treatment recommendations, which is exactly why your internal protocol has to be explicit and defensible.
- Bake FWA controls around the new revenue. Enhanced per diems and SCAs draw payer SIU attention. Clean claim rate, denial rate by payer, and documentation completeness should be on the QAPI dashboard, not buried in the RCM vendor’s monthly report.
The Joint Commission accreditation surveys AHS supported in May 2026, covering five facilities across three states and three levels of care, every one of them turned on whether the clinical record could defend what the contracting team was billing. The two functions cannot operate in separate buildings anymore.
Frequently asked questions
How do we justify longer detox length of stay for xylazine or nitazene exposure when the payer’s grid still reflects standard opioid withdrawal timelines?
Submit a medical-necessity narrative that pairs toxicology confirmation with a documented withdrawal trajectory. Cite the delayed onset and prolonged course of fentanyl plus xylazine withdrawal, the alpha-2 component, and the ASAM Criteria 4th Edition dimensional assessment supporting continued stay. Pre-load the chart with autonomic vital-sign trends, COWS plus an alpha-2 withdrawal scale, and physician documentation of why the patient does not yet meet step-down criteria. If the grid says five days and the patient needs nine, the chart has to answer the question before the UR nurse asks it.
What belongs in a single-case agreement (SCA) request for a complex synthetic-drug admission?
Patient-specific toxicology, the proposed level of care, expected length of stay, the proposed per diem with a clear delta from your standard rate, co-occurring conditions (wound care, cardiovascular instability, psychiatric acuity), and a statement that in-network options do not exist or cannot provide the required level of care within a reasonable geographic and clinical window. Attach your accreditation status, licensure, and outcomes data. Get it signed before admission whenever possible.
Can MHPAEA help when commercial payers deny extended residential SUD stays for polysubstance synthetic cases?
Yes. If the plan applies more restrictive concurrent review standards, prior authorization criteria, or medical-necessity thresholds to SUD residential than to comparable medical/surgical inpatient admissions, that is an NQTL question. The 2024 MHPAEA Report to Congress confirms EBSA is actively reviewing comparative analyses and obtaining corrections. Cite the parity framework in the appeal, and if the denial pattern is systemic, escalate to DOL EBSA or the state insurance department.
How should clinical documentation change so utilization review nurses approve atypical detox protocols?
Clinicians should stop writing notes only for the next shift and start writing them for the UR nurse reviewing the chart against a grid. Every day of continued stay should have: a current ASAM dimensional summary, objective withdrawal data, why a lower level of care is not yet appropriate, and the specific clinical event or finding that drove the decision. If the patient is on day seven of a xylazine-complicated course, day seven’s note has to say so explicitly.
What credentialing or licensing exposure do we create by admitting higher-acuity synthetic-drug patients to a residential level of care?
Two big ones. First, your residential or 3.7 residential withdrawal management license has scope limits; admitting patients who clinically need medically managed inpatient care can trigger a state DOH or DCF citation. Second, your payer credentialing application and contract describe the populations you serve and the services you provide. If you start billing higher-acuity codes or pursuing SCAs for clinical populations outside your credentialed scope, you create payer audit and recoupment exposure. Update your medical staff bylaws, scope-of-service documents, and credentialing files before, not after, the case mix shifts.
References
- CDC NCHS Data Brief No. 549, Drug Overdose Deaths in the United States, 2023–2024 (January 2026)
- CDC, About Overdose Prevention (provisional 2026 data and polysubstance findings)
- DEA Public Safety Advisory, May 12, 2026 (xylazine, nitazenes, cychlorphine, medetomidine)
- DEA Diversion Control Division, Nitazenes scheduling actions
- Journal of Medical Toxicology, Tianeptine Exposures Reported to United States Poison Centers, 2015–2023
- Penn CAMP, Best Practices for Management of Xylazine Withdrawal and Xylazine-related Overdose
- PMC, Management of xylazine toxicity, overdose, dependence, and withdrawal: A systematic review
- DOL/HHS/Treasury, 2024 MHPAEA Report to Congress